FDA analysis finds Johnson & Johnson's single-dose COVID-19 vaccine protects against virus

I would imagine that the Johnson, the J and J, uh, will be putting in for an emergency use authorization, I would imagine literally bit within a week or two. Uh, then it's up to the FDA. I don't want to get ahead of them and predict what they'll do. But the data look robust enough that they likely will go ahead with it. Which means probably by sometime mid two and February, we start to be getting some doses in. The efficacy in the United States was 72% now. At first glance, that might not seem as good as 94 95%. But the important part of the whole thing was that for advanced severe disease, it was quite effective. Overall, it was about 85% effective, and there were no hospitalizations or deaths in the individuals who were vaccinated, which is very good news. It is clearly value added both in the United States and importantly for developing nations for the following reasons. It's a single dose vaccine, not a two dose vaccine. It's relatively inexpensive. It doesn't require a very stringent cold chain as a you know, minus 90 some odd degrees, Um, for a freeze, it just requires a refrigerator

코인카지노

Johnson & Johnson맥스카지노�s single-dose vaccine protects against COVID-19, according to an analysis by U.S. regulators Wednesday that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic.The Food and Drug Administration맥스카지노�s scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. The agency also said J&J's shot 맥스카지노� one that could help speed vaccinations by requiring just one dose instead of two 맥스카지노� is safe to use.That맥스카지노�s just one step in the FDA맥스카지노�s evaluation of a third vaccine option for the U.S. On Friday, the agency맥스카지노�s independent advisers will debate if the evidence is strong enough to recommend the long-anticipated shot. Armed with that advice, FDA is expected to make a final decision within days.The vaccination drive has been slower than hoped, hampered by logistical issues and weather delays even as the country mourns more than 500,000 virus-related deaths. So far, about 65 million Americans have received at least one dose of vaccine made by Pfizer or Moderna, shots that require two doses several weeks apart for full protection.J&J tested its single-dose option in 44,000 people in the U.S., Latin America and South Africa. Because different mutated versions of the virus are circulating in different countries, researchers analyzed the results geographically. J&J previously announced the vaccine worked better in the U.S. 맥스카지노� 72% effective against moderate to severe COVID-19, compared with 66% in Latin America and 57% in South Africa.Still, in every country, it was highly effective against the most serious symptoms, and early study results showed no hospitalizations or deaths starting 28 days after vaccination.While the overall effectiveness numbers may suggest the J&J candidate isn't quite as strong as two-dose competitors, all of the world맥스카지노�s COVID-19 vaccines have been tested differently, making comparisons nearly impossible. While it wouldn맥스카지노�t be surprising if one dose turns out to be a little weaker than two doses, policymakers will decide if that맥스카지노�s an acceptable trade-off to get more people vaccinated faster.J&J was on track to become the world's first one-dose option until earlier this month, Mexico announced it would use a one-dose version from China's CanSino. That vaccine is made with similar technology as J&J's but initially was developed as a two-dose option until beginning a one-dose test in the fall.The rival Pfizer and Moderna vaccines being used in the U.S. and numerous other countries must be kept frozen, while the J&J shot can last three months in the refrigerator, making it easier to handle. AstraZeneca's vaccine, widely used in Europe, Britain and Israel, is made similarly and also requires refrigeration but takes two doses.If the FDA clears the J&J shot for U.S. use, it won맥스카지노�t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week. But J&J told Congress this week that it expected to provide 20 million doses by the end of March and 100 million by summer.European regulators and the World Health Organization also are considering J&J맥스카지노�s vaccine. Worldwide, the company aims to be producing around a billion doses by the end of the year.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute맥스카지노�s Department of Science Education. The AP is solely responsible for all content.

The Food and Drug Administration맥스카지노�s scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. The agency also said J&J's shot 맥스카지노� one that could help speed vaccinations by requiring just one dose instead of two 맥스카지노� is safe to use.

코인카지노

That맥스카지노�s just one step in the FDA맥스카지노�s evaluation of a third vaccine option for the U.S. On Friday, the agency맥스카지노�s independent advisers will debate if the evidence is strong enough to recommend the long-anticipated shot. Armed with that advice, FDA is expected to make a final decision within days.

The vaccination drive has been slower than hoped, hampered by logistical issues and weather delays even as the country mourns more than 500,000 virus-related deaths. So far, about 65 million Americans have received at least one dose of vaccine made by Pfizer or Moderna, shots that require two doses several weeks apart for full protection.

J&J tested its single-dose option in 44,000 people in the U.S., Latin America and South Africa. Because different mutated versions of the virus are circulating in different countries, researchers analyzed the results geographically. J&J previously announced the vaccine worked better in the U.S. 맥스카지노� 72% effective against moderate to severe COVID-19, compared with 66% in Latin America and 57% in South Africa.

Still, in every country, it was highly effective against the most serious symptoms, and early study results showed no hospitalizations or deaths starting 28 days after vaccination.

While the overall effectiveness numbers may suggest the J&J candidate isn't quite as strong as two-dose competitors, all of the world맥스카지노�s COVID-19 vaccines have been tested differently, making comparisons nearly impossible. While it wouldn맥스카지노�t be surprising if one dose turns out to be a little weaker than two doses, policymakers will decide if that맥스카지노�s an acceptable trade-off to get more people vaccinated faster.

J&J was on track to become the world's first one-dose option until earlier this month, Mexico announced it would use a one-dose version from China's CanSino. That vaccine is made with similar technology as J&J's but initially was developed as a two-dose option until beginning a one-dose test in the fall.

The rival Pfizer and Moderna vaccines being used in the U.S. and numerous other countries must be kept frozen, while the J&J shot can last three months in the refrigerator, making it easier to handle. AstraZeneca's vaccine, widely used in Europe, Britain and Israel, is made similarly and also requires refrigeration but takes two doses.

If the FDA clears the J&J shot for U.S. use, it won맥스카지노�t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week. But J&J told Congress that it expected to provide 20 million doses by the end of March and 100 million by summer.

European regulators and the World Health Organization also are considering J&J맥스카지노�s vaccine. Worldwide, the company aims to be producing around a billion doses by the end of the year.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute맥스카지노�s Department of Science Education. The AP is solely responsible for all content.

FDA analysis finds Johnson & Johnson's single-dose COVID-19 vaccine protects against virus

Share

Share

Share

Top Picks